Novartis broadens BRAF/MEK cancer combo use, winning tumor-agnostic approval in patients 6 and up
Novartis nabbed another FDA win for its Tafinlar and Mekinist cancer combo, this time broadening its label quite widely.
US regulators greenlighted the therapy for any solid tumor in patients with BRAF V600E mutations whose cancers are unresectable or metastatic. Individuals as young as 6 will be eligible to take the drug, making it the first BRAF/MEK inhibitor approved in pediatrics, Novartis said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.